Envestnet Asset Management’s Legend Biotech LEGN Stock Holding History

Envestnet Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$469K	Buy	+16,234	New	+$438K	﹤0.01%	4129

Other funds holding LEGN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

IAMH

IvyRock Asset Management (HK) Sheung Wan, Hong Kong $177M AUM 10.49% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

IGAM

iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Envestnet Asset Management's LEGN Position: Q2 2026 in Review

Envestnet Asset Management opened a new position in Legend Biotech (LEGN) in Q2 2026: 16,234 shares worth $469K. The stake represents ﹤0.01% of the portfolio and ranks #4129 among its holdings.

66 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Envestnet Asset Management held 16,234 shares of Legend Biotech worth $469K as of Q2 2026.
Legend Biotech was a new Envestnet Asset Management position in Q2 2026.
Legend Biotech made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4129 holding.
66 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.